Brian Neff, MD
Otolaryngology · Rochester, MNNPI 1639156920
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $15,625 of the $16,345 with a category attached, or 95.6%. Cochlear Americas accounts for 97.2% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $15,805, more than ten times the $143 reported in 2020. Among otolaryngology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 9 payments — averaging $1816.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cochlear Americas$16K
- Advanced Bionics, LLC$321
- Acclarent, Inc$134
Across 4 payments — averaging $13,586 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$54K
What the payments were for
- Travel & lodging$15,62596%
- Food & beverage$7204%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cochlear Americas | 4 | $15,890 |
| Advanced Bionics, LLC | 4 | $321 |
| Acclarent, Inc | 1 | $134 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,345 in reported general payments places this provider in the 95th percentile of 181 otolaryngology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dexamethasone Sodium Phosphate | 11 | $552 |
| Nortriptyline Hcl | 18 | $295 |
| Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid | 13 | $142 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Rochester
- Matthew CarlsonRochester$80K
- Rijul KshirsagarRochester$18K
- Carlos Pinheiro NetoRochester$11K
- Dale EkbomRochester$9K
- Terenece ZimmermannRochester$7K
- James DornhofferRochester$5K
- Colin DriscollRochester$5K
- Joshua WiedermannRochester$4K
- Eleni RettigRochester$4K
- Jacob DeyRochester$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.